User:Mr. Ibrahem/Panobinostat
Clinical data | |
---|---|
Trade names | Farydak |
Other names | LBH-589 |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | By mouth (capsules) |
Drug class | Histone deacetylase inhibitor (HDAC inhibitor)[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 21%[2] |
Protein binding | 90%[2] |
Metabolism | CYP3A (40%), CYP2D6, CYP2C19[2] |
Elimination half-life | 37 hours[2] |
Excretion | Fecal (44–77%), renal (29–51%)[2] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C21H23N3O2 |
Molar mass | 349.434 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Panobinostat, sold under the brand name Farydak, is a medication used to treat multiple myeloma.[1] It is used when at least two other treatments have failed.[1] It is taken by mouth.[1] It is used together with bortezomib and dexamethasone.[1]
Common side effects include diarrhea, tiredness, nausea, swelling, fever, weight loss, high magnesium, low calcium, low potassium, low white blood cells, and low platelets.[3] Other side effects may include bleeding, QT prolongation, and infections.[3] Use during pregnancy may harm the baby.[3] It is a histone deacetylase inhibitor (HDAC inhibitor).[1]
Panobinostat was approved for medical use in the United States and Europe in 2015.[3][4] In the United Kingdom six doses costs the NHS about £4,700 as of 2021.[1] This amount in the United States costs about 15,000 USD.[5]
References[edit]
- ^ a b c d e f g h i BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 979. ISBN 978-0857114105.
- ^ a b c d e "Panobinostat Package Insert" (PDF). Archived (PDF) from the original on 2021-04-10. Retrieved 2021-07-07.
- ^ a b c d e "Panobinostat Monograph for Professionals". Drugs.com. Archived from the original on 9 July 2021. Retrieved 26 October 2021.
- ^ "Farydak product details". European Medicines Agency. Archived from the original on 2018-06-20. Retrieved 2022-03-14.
- ^ "Farydak Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 May 2021. Retrieved 26 October 2021.